IMUC Company Description

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases.

Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis.

The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases.

Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

EOM Pharmaceuticals Holdings, Inc.

Country	United States
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Irach Taraporewala

Contact Details

Address: 136 Summit Avenue Montvale, 07645 United States
Phone	201 351 0605
Website	eompharma.com

Stock Details

Ticker Symbol	IMUC
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US4525364026
SIC Code	2834

Key Executives

Name	Position
Dr. Irach B. Taraporewala B.S., M.S., Ph.D.	Chief Executive Officer, President and Director
Wayne I. Danson CPA	Chief Financial Officer and Treasurer
Eli Goldberger	Founder, Chairman and Chief Operating Officer
Dr. Shalom Z. Hirschman M.D.	Co-Founder, Chief Scientific Officer and Medical Director